MRNA vs PFE
Moderna, Inc. vs Pfizer Inc. · Updated Mar 28, 2026
MRNA — 5 winsPFE — 14 wins
Price Performance
MRNA +59.25%PFE +7.26%
Performance
| MRNA | PFE | |
|---|---|---|
| 1 Month | -2.90% | -0.17% |
| 3 Months | +54.48% | +8.09% |
| 6 Months | +92.74% | +14.64% |
| YTD | +69.14% | +8.65% |
| 1 Year | +47.36% | +7.32% |
| 3 Year | -73.73% | -47.28% |
| 5 Year | -19.55% | -26.60% |
Yearly Returns
| YTD | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MRNA | +60.6% | -30.1% | -63.0% | -44.4% | -23.6% | +127.3% | +443.3% | +27.6% | -17.9% | — | — | — |
| PFE | +7.4% | -6.4% | -10.8% | -43.8% | -9.4% | +60.4% | -0.8% | -9.4% | +19.8% | +9.8% | +1.6% | +3.0% |
Valuation
| MRNA | PFE | |
|---|---|---|
| P/E Ratio | — | 19.89 |
| Forward P/E | — | 9.36 |
| PEG Ratio | 0.26 | — |
| P/S Ratio | 10.42 | 2.45 |
| P/B Ratio | 2.34 | 1.77 |
| EV/EBITDA | -7.69 | 13.09 |
Financials
| MRNA | PFE | |
|---|---|---|
| EPS (TTM) | $-7.27 | $1.36 |
| Gross Margin | +33.33% | +69.97% |
| Operating Margin | -126.40% | -9.35% |
| Net Margin | -121.83% | -9.34% |
| ROE | -32.62% | +9.00% |
| ROA | -22.87% | +3.75% |
| Debt/Equity | 0.22 | 0.78 |
Growth
| MRNA | PFE | |
|---|---|---|
| Revenue Growth YoY | -29.81% | -1.16% |
| Revenue Growth QoQ | -33.27% | +5.42% |
| EPS Growth YoY | +27.49% | -514.29% |
| EPS Growth QoQ | -313.73% | -146.77% |
Technical
| MRNA | PFE | |
|---|---|---|
| RSI (14) | 51.82 | 47.28 |
| % From 20-Day SMA | -6.07% | +0.16% |
| % From 50-Day SMA | +3.18% | +0.93% |
| % From 200-Day SMA | +51.35% | +6.58% |
| % From 52-Week High | -16.24% | -3.17% |
| % From 52-Week Low | +123.88% | +29.36% |
Analyst Ratings
MRNA
Hold(14 analysts)
Strong SellHoldStrong Buy
Price Target
$35.67
-29.79% upside
PFE
Hold(12 analysts)
Strong SellHoldStrong Buy
Price Target
$27.50
+2.36% upside
Overview
| MRNA | PFE | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - General |
| Exchange | NASDAQ | NYSE |
| Market Cap | $20.25B | $153.44B |
| Shares Outstanding | 394.9M | 5.69B |
| Avg Volume (10D) | 6.63M | 41.21M |
| Dividend Yield | — | 6.37% |
Frequently Asked Questions
Is MRNA or PFE a better buy right now?
Based on 19 comparable metrics, PFE leads in 14 categories while MRNA leads in 5. PFE has a consensus analyst rating with 12 analysts covering the stock. Neither stock should be purchased based on a single comparison — consider your investment goals and risk tolerance.
Which stock has better performance, MRNA or PFE?
Over the past year, MRNA returned +47.36% compared to PFE's +7.32%. In the short term (1 month), MRNA returned -2.90% vs PFE's -0.17%.
Is MRNA or PFE more expensive?
MRNA trades at a P/E of — compared to PFE's 19.89. On a price-to-sales basis, MRNA trades at 10.42x vs PFE's 2.45x. Forward P/E: MRNA at — vs PFE at 9.36.
Which stock has higher growth, MRNA or PFE?
MRNA's revenue grew -29.81% year-over-year compared to PFE's -1.16%. EPS growth: MRNA at +27.49% vs PFE at -514.29%.
Do MRNA and PFE pay dividends?
MRNA does not currently pay a dividend. PFE pays a dividend with a yield of 6.37%.
Which stock do analysts prefer, MRNA or PFE?
MRNA has 14 analysts with a target price of $35.67 (-29.79% upside). PFE has 12 analysts with a target of $27.50 (+2.36% upside).
Data updated daily. All comparisons based on latest available market data. Not investment advice.